Solaraze U.S. Autumn Launch Likely After Bioglan Purchase From SkyePharma
Executive Summary
Bioglan Pharma is projecting an August/September launch in North America for its actinic keratoses product Solaraze (diclofenac gel, 3%) following a licensing agreement with SkyePharma.